©2025 Stanford Medicine
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
Not Recruiting
Trial ID: NCT00458601
Purpose
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.
Official Title
A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Stanford Investigator(s)
Lawrence D Recht
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
* Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.
* Gross total resection followed by conventional chemoradiation therapy without progression of disease.
Exclusion Criteria:
* Presence of diffuse leptomeningeal disease or gliomatosis cerebri.
* Systemic corticosteroid therapy \> 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.
* Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.
* Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.
Intervention(s):
drug: Temozolomide
drug: CDX-110 with GM-CSF
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061